// App-Quantinova.ai

e20037 : Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.

Researchers

Presenter

  • Eric Maiese

Principal Investigators

  • Christopher N. Graham

  • Emma Hawe

  • Jean-Gabriel Le Moine

Medical Centers

  • Janssen Scientific Affairs, Horsham, PA

  • RTI Health Solutions, Research Triangle Park, NC

  • RTI Health Solutions, Manchester, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • JB Medical Ltd.

  • RTI Health Solutions

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Bortezomib

  • ZoMaxx

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved